Selective Inhibition of the ABCG2 Transporter by Primaquine Derivatives Reverses the Multidrug Resistance of Tumor Cells
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26115367 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Marija Mioč und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička c. 54, 10000 Zagreb, Croatia. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily G, Member 2, Drug Resistance, Neoplasm, Neoplasm Proteins, Primaquine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Croatian Science Foundation, European Regional Development Fund.
Abstract (Originalsprache)
Multidrug resistance (MDR) poses a significant challenge in cancer therapy, often leading to treatment failure and relapse. ATP-binding cassette (ABC) transporters, particularly ABCG2, play a pivotal role in MDR development by actively expelling chemotherapeutic agents from cancer cells. This study investigates the effects of two groups of primaquine derivatives—fumardiamides (1a–d) and bis-ureas (2a, b), both bearing halogenated benzene rings—on the activity of P-glycoprotein (P-gp) and ABCG2. Their potential to reverse MDR was evaluated through a series of functional assays aimed at comparing transporter–compound interactions. The results indicated that fumardiamide derivatives, specifically 1a, 1b, and 1d, exhibited potent inhibition of ABCG2 while having no effect on P-gp, demonstrating a selective mode of action. The tested derivatives displayed low to moderate cytotoxicity and did not affect ABCG2 expression or localization. Moreover, these compounds enhanced the sensitivity of drug-resistant cancer cell lines to mitoxantrone, underscoring their potential to overcome ABCG2-mediated MDR. These findings suggest that chemical modifications of primaquine, particularly the incorporation of fumardiamide moieties, confer novel biological properties, providing promising leads for the development of selective ABCG2 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička c. 54, 10000 Zagreb, Croatia.
- Department of Medicinal Chemistry, University of Zagreb Faculty of Pharmacy and Biochemistry, A. Kovačića 1, 10000 Zagreb, Croatia.
- Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Magyar Tudósok krt. 2, 1117 Budapest, Hungary.
ORCID-Profile: Marija Mioč, Maja Beus, Karla Carević, Zrinka Rajić, Ágnes Telbisz, Marijeta Kralj
Förderung
- Croatian Science Foundation
- European Regional Development Fund
Zitieren
APA
Mioč, M., Beus, M., Carević, K., Rajić, Z., Sarkadi, B., Telbisz, Á., & Kralj, M. (2025). Selective Inhibition of the ABCG2 Transporter by Primaquine Derivatives Reverses the Multidrug Resistance of Tumor Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115367
Vancouver
Mioč M, Beus M, Carević K, Rajić Z, Sarkadi B, Telbisz Á, et al. Selective Inhibition of the ABCG2 Transporter by Primaquine Derivatives Reverses the Multidrug Resistance of Tumor Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115367
BibTeX
@article{Mio2025,
author = {Mioč, Marija and Beus, Maja and Carević, Karla and Rajić, Zrinka and Sarkadi, Balázs and Telbisz, Ágnes and Kralj, Marijeta},
title = {Selective Inhibition of the ABCG2 Transporter by Primaquine Derivatives Reverses the Multidrug Resistance of Tumor Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26115367}
}
EUVIMED